Regrettably, only a fraction of published medical research is reproducible by other investigators. This is no surprise to those of us who contribute or follow medical advancements. Hundreds of reviews have documented tens of thousands of examples. From cancer biology...
How might an investor protect themselves from the recent inflationary spike? How might they rationally act as the news is worsening? From a macroeconomic investor perspective, I offer caution in reacting to the news. The crescendo of news transmits multiple signals....
Human versus machine. Which is superior? It’s a centuries-old question that continues to fascinate us. Regrettably, for investors, it often fascinates to the point of distraction. But, investors are only human. And when investors are both the questioner and a...
by Guillaume Detrait, President & Chief Risk Officer [email protected] During my 13-year tenure at Welton, I’ve overseen periods of growth, change, and the 2020 Covid pandemic crisis. And while each of these periods brought its own unique challenges, one...
For macroeconomic investors the passage of this bill is a watershed event, but its implications for what comes next are likely even more consequential. The new $1.9T economic relief package that was passed by Congress this week and signed into law yesterday, is...
You are now leaving Welton’s website and will be redirected to a third‑party website. The material on that site is prepared by an independent third party that is not affiliated with or controlled by Welton. Welton does not endorse or assume responsibility for the accuracy or completeness of any information on that site. This link is provided for informational purposes only and should not be construed as a recommendation or solicitation.
